|1.||Schally, Andrew V: 21 articles (12/2014 - 02/2002)|
|2.||Emons, Günter: 20 articles (06/2014 - 01/2002)|
|3.||Gründker, Carsten: 19 articles (06/2014 - 01/2002)|
|4.||Conn, P Michael: 14 articles (01/2012 - 05/2002)|
|5.||Janovick, Jo Ann: 13 articles (04/2011 - 05/2002)|
|6.||Limonta, Patrizia: 12 articles (01/2015 - 08/2002)|
|7.||Montagnani Marelli, Marina: 11 articles (01/2015 - 08/2002)|
|8.||Moretti, Roberta M: 10 articles (01/2015 - 08/2002)|
|9.||Millar, Robert P: 10 articles (04/2014 - 10/2004)|
|10.||Leung, Peter C K: 10 articles (01/2013 - 07/2002)|
06/01/2008 - "We conclude that the GnRH-p53 fusion strategy may provide a basis for constructing an effective cancer therapeutic for patients with tumors in GnRH-receptor-positive tissue types."
05/01/2014 - "Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors."
11/01/2015 - "It is reported that several cancer cells also express LHRH receptors such as breast, ovarian, prostatic, bladder and others. "
11/01/2014 - "Direct antiproliferative effect of these was investigated on three GnRH-receptor positive cancer cells, PC-3, LNCaP and DU145. "
05/01/2014 - "EP-100 was well tolerated in patients with advanced, LHRH-receptor-expressing solid tumors. "
|2.||Prostatic Neoplasms (Prostate Cancer)
10/01/2013 - "Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies."
07/01/2013 - "GnRH receptor antagonists for prostate cancer."
04/30/2013 - "Differential signaling of the GnRH receptor in pituitary gonadotrope cell lines and prostate cancer cell lines."
06/01/2011 - "LHRH receptor expression on prostate cancer cells has led to the rational design of many new compounds. "
06/01/2011 - "The selective and persistent expression of these receptors in prostate cancer cells is the rationale for LHRH receptor targeted agents. "
|3.||Ovarian Neoplasms (Ovarian Cancer)
01/01/2013 - "We have analyzed in vitro whether inhibition of glycolysis can reduce the viability of human endometrial and ovarian cancer cells and whether it can enhance the antitumor efficacy of GnRH receptor-targeted therapies. "
08/01/2012 - "EP-100 is a membrane-disrupting peptide targeted to LHRH receptors, which is undergoing early clinical studies in ovarian cancer patients."
06/01/2014 - "Fifty-five of 59 (93%) of ovarian cancer samples screened expressed LHRH receptors. "
01/01/2013 - "In addition, cotreatment of a glycolysis inhibitor with GnRH receptor-targeted therapies might be a suitable therapy for GnRH receptor-positive human endometrial and ovarian cancers."
11/01/2003 - "Surgically removed ovarian cancers were screened for GnRH receptor expression prior to subcellular fractionations. "
|4.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
10/01/2010 - "Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia."
08/01/2001 - "One study evaluated LHRH receptors in hormone-dependent PC tissue, but no data have thus far been obtained on the presence of LHRH receptors in benign prostatic hyperplasia (BPH) and especially hormone-refractory PC in patients. "
11/01/2009 - "Expression of mRNA for human type-I LHRH receptor transcript forms in human benign prostatic hyperplasia."
01/01/1988 - "Prolactin and luteinizing hormone-releasing hormone receptors in human benign prostatic hyperplasia and prostate cancer."
11/01/2010 - "To assess the mechanism by which the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix exerts its effects in men with benign prostatic hyperplasia (BPH), as it produces a long-lasting improvement in lower urinary tract symptoms that is only partly accounted for by the transient reduction in testosterone levels, and the beneficial results could be due to direct inhibitory effects of cetrorelix on the prostate exerted through prostatic LHRH receptors. "
01/01/2012 - "Integrated pharmacometrics and systems pharmacology model-based analyses to guide GnRH receptor modulator development for management of endometriosis."
04/01/2003 - "Considering that TAK-013 has more potent antagonistic properties for human GnRH receptor than for monkey receptor, our data suggest that TAK-013 would be effective for reproductive disorders such as endometriosis and uterine leiomyoma and useful for assisted reproductive technology procedures."
01/25/2000 - "The present study was conducted to investigate whether GnRH-receptor (GnRH-R) gene is expressed in endometriosis ovarian implants and whether a GnRH-analogue (GnRH-a) may exert an effect on endometriosis cell proliferation in vitro. "
04/15/2010 - "Antagonism of the gonadotropin releasing hormone (GnRH) receptor has resulted in positive clinical results in reproductive tissue disorders such as endometriosis and prostate cancer. "
07/01/2008 - "Antagonism of the gonadotropin releasing hormone (GnRH) receptor has shown positive clinical results in numerous reproductive tissue disorders such as endometriosis, prostate cancer and others. "
|1.||Gonadotropin-Releasing Hormone (GnRH)
|7.||AN 204 (AN 201)
|8.||LH Receptors (LH Receptor)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)